Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied

Trial Details

NCT ID
NCT05819892
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Paclitaxel
  • Carboplatin
  • Dostarlimab
  • Cisplatin
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients are eligible to participate on this study only if they meet all of the following inclusion criteria.
  • Has read and understands the informed consent form (ICF) and has given written informed consent prior to any study procedures
  • Have surgically staged IIIC, pathologically confirmed endometrial cancer of any histologic subtype and be eligible for adjuvant chemoradiation foll…
  • Enrolled within 8 weeks of surgery and started treatment within 10 weeks of surgery

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →